利用DNA和RNA测序鉴别子宫平滑肌瘤与平滑肌肉瘤
本研究对13例子宫平滑肌瘤和13例子宫平滑肌肉瘤的福尔马林固定石蜡包埋样本进行靶向DNA和RNA测序,比较拷贝数变异、单核苷酸变异、小插入/缺失及基因融合等差异。平滑肌肉瘤的肿瘤突变负荷更高,并发现新的差异性基因靶点,为术前鉴别诊断提供新思路。
要点
- 平滑肌肉瘤的拷贝数变异、单核苷酸变异、小插入/缺失及基因融合负荷均高于平滑肌瘤。
- 平滑肌肉瘤中20个基因发生缺失、19个基因发生重复,平滑肌瘤分别为6个和3个。
- 1例初诊平滑肌肉瘤经测序重新诊断为携带新型ALK-TNS1融合的炎性肌纤维母细胞瘤。
核心结论
- 通过整合比较基因组和转录组分析,识别出可能区分平滑肌肉瘤与平滑肌瘤的新型差异性基因靶点,为这些子宫肌层肿瘤的鉴别诊断提供新见解。
研究设计与样本
- 对13例子宫平滑肌瘤和13例子宫平滑肌肉瘤的福尔马林固定石蜡包埋样本进行实体瘤相关基因DNA和RNA编码区靶向测序,DNA测序识别拷贝数变异、单核苷酸变异和小插入/缺失,RNA测序识别基因融合、剪接变异和/或差异基因表达谱。
主要发现
- 平滑肌肉瘤的肿瘤突变负荷在拷贝数变异、单核苷酸变异、小插入/缺失和基因融合方面均高于平滑肌瘤。
- 平滑肌肉瘤中20个基因受缺失影响,平滑肌瘤中观察到6个基因缺失;平滑肌肉瘤中19个基因 identified 重复(重复),平滑肌瘤中仅3个基因。
- 所有分析的平滑肌肉瘤中最常见的突变(单核苷酸变异和插入/缺失)见于105个基因,平滑肌瘤中82个基因受影响。
- 1例初诊为平滑肌肉瘤的肿瘤在本研究中被确定为携带新型ALK-TNS1融合的炎性肌纤维母细胞瘤。
- 在分析的55个基因中,平滑肌肉瘤有11个基因显示差异性转录组谱;8.5%的初诊平滑肌肉瘤显示与这些肿瘤相关的高置信度新型基因融合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although uterine leiomyomas and leiomyosarcomas are considered biologically unrelated tumors, they share morphologic and histologic characteristics that complicate their differential diagnosis. The long-term therapeutic option for leiomyoma is laparoscopic myomectomy with morcellation, particularly for patients who wish to preserve their fertility. However, because of the potential dissemination of undiagnosed or hidden leiomyosarcoma from morcellation, there is a need to develop a preoperative assessment of malignancy risk. OBJECTIVE: Through an integrated comparative genomic and transcriptomic analysis, we aim to identify differential genetic targets in leiomyomas vs leiomyosarcomas using next-generation sequencing as the first step toward preoperative differential diagnosis. STUDY DESIGN: Targeted sequencing of DNA and RNA coding regions for solid tumor-associated genes was performed on formalin-fixed paraffin-embedded samples from 13 leiomyomas and 13 leiomyosarcoma cases. DNA sequencing was used to identify copy number variations, single-nucleotide variants, and small insertions/deletions. RNA sequencing was used to identify gene fusions, splice variants, and/or differential gene expression profiles. RESULTS: In leiomyosarcomas, tumor mutation burden was higher in terms of copy number variations, single nucleotide variants, small insertions/deletions, and gene fusions compared with leiomyomas. For copy number variations, 20 genes were affected by deletions in leiomyosarcomas, compared with 6 observed losses in leiomyomas. Gains (duplications) were identified in 19 genes in leiomyosarcomas, but only 3 genes in leiomyomas. The most common mutations (single-nucleotide variants and insertions/deletions) for leiomyosarcomas were identified in 105 genes of all analyzed leiomyosarcomas; 82 genes were affected in leiomyomas. Of note, 1 tumor previously diagnosed as leiomyosarcoma was established as inflammatory myofibroblastic tumor along this study with a novel ALK-TNS1 fusion. Finally, a differential transcriptomic profile was observed for 11 of 55 genes analyzed in leiomyosarcomas; 8.5% of initially diagnosed leiomyosarcomas showed high-confidence, novel gene fusions that were associated with these tumors. CONCLUSION: Through integrated comparative genomic and transcriptomic analyses, we identified novel differential genetic targets that potentially differentiate leiomyosarcomas and leiomyomas. This provides a new insight into the differential diagnosis of these myometrial tumors.
引用
- Mas A, Alonso R, Garrido-Gómez T, et al. The differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing. Am J Obstet Gynecol. 2019. PMID: 31121144. doi:10.1016/j.ajog.2019.05.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。